To summarize, SRPK1 downregulation affects both tumor epithelial cells and endothelial cells of the microenvironment, whilst it suppresses the acquisition of CSC phenotype, migration, invasion, metastasis, and angiogenesis and promotes apoptosis in preclinical NSCLC models. Here, SRPK1 is linked to non-small cell lung carcinoma.